Method for treating or preventing a neural disorder with a neurotrophic growth factor

• US 20060122135A1
• Filed: 03/08/2005
• Published: 06/08/2006
• Est. Priority Date: 07/14/1998
• Status: Abandoned Application

• Current Assignee: Hugo Alfons Gabriel Geerts, Stefan Leo Jozef Masure, Theo Frans Meert
• Original Assignee: Hugo Alfons Gabriel Geerts, Stefan Leo Jozef Masure, Theo Frans Meert
• Inventors: Gabriel Geerts, Hugo Alfons, Meert, Theo Frans, Masure, Stefan Leo Jozef
• Application Number:
  US11/074,497
• Publication Number:
  US 20060122135A1
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 14/48 Nerve growth factor [NGF]

Abstract

There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid sequence from position 27 to 139 of the sequence illustrated in FIG. 1, or a functional equivalent, derivative or bioprecursor thereof. The nucleic acid molecule encoding enovin can be used to transform a host cell, tissue or organism by including it in an appropriate vector. The host cell, tissue or organism and the vector also form part of the invention.

Claims

1-57. -57. (canceled)

58. A method for treating or preventing a neural disorder in a subject the method comprising administering to the subject an amount of a human neurotrophic growth factor polypeptide comprising the amino acid sequence of SEQ ID NO:

3, or a functional equivalent derivative thereof, in a sufficient concentration to reduce or prevent the symptoms of the neural disorder.

59. A method according to claim 58, wherein the neural disorder is selected from the group consisting of:

Parkinson'"'"'s disease, Alzheimer'"'"'s disease, neuronal disorders associated with expanded polyglutamine sequences such as Huntington'"'"'s disease, peripheral neuropathy, neuropathic pain;

acute brain injury, nervous system tumors, multiple sclerosis, amyotrophic lateral sclerosis, peripheral nerve trauma, injury exposure to neurotoxins, multiple endocrine neoplasia, familial Hirschsprung disease, prion associated diseases, Creutzfeld-Jacob disease, cancer or stroke.

60. A method according to claim 58, wherein the functional equivalent derivative comprises an amino acid sequence having at least 90% homology to SEQ ID NO:

3.

61. A method according to claim 60, wherein the functional equivalent derivative comprises SEQ ID NO:

9 or SEQ ID NO;

10.